# A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

> **NCT07181694** · PHASE1 · RECRUITING · sponsor: **Biocad** · enrollment: 444 (estimated)

## Conditions studied

- Healthy Adult Male

## Interventions

- **DRUG:** Adalimumab (BCD-057) 100 mg/mL
- **DRUG:** Adalimumab (BCD-057) 50 mg/mL
- **DRUG:** Adalimumab (Humira) 100 mg/mL

## Key facts

- **NCT ID:** NCT07181694
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 444 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07181694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07181694, "A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07181694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*